Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633371 | 0.75 | GABRP (0.43) | NOS3NOS1NOS2CHRM1 | |
| SCHEMBL12384299 | 0.74 | ALDH1A1 (0.38) | CHRM1 | |
| SCHEMBL6753704 | 0.72 | CHRM1 (0.38) | NOS3NOS1NOS2CHRM1 | |
| SCHEMBL25955713 | 0.71 | CHRM1 (0.35) | CHRM1 | |
| SCHEMBL13770949 | 0.71 | CHRNB2 (0.46) | CHRM1 | |
| SCHEMBL14280513 | 0.71 | CHRM1 (0.32) | CHRM1 | |
| SCHEMBL22912887 | 0.69 | USP2 (0.36) | CHRM1 | |
| SCHEMBL3134016 | 0.69 | CHRM1 (0.37) | CHRM1 | |
| SCHEMBL14207594 | 0.69 | MEN1 (0.39) | CHRM1 | |
| SCHEMBL7942491 | 0.68 | CHRM1 (0.48) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | claimed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | NOS3 1875/4885NOS1 917/4885NOS2 1240/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | NOS3 1875/4885NOS1 917/4885NOS2 1240/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | NOS3 2442/4885NOS1 1647/4885NOS2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.